The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Next-generation CAR-T strategies aim to improve access and durability in myeloma
Binod Dhakal, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the evolving landscape of next-generation CAR-T strategies in multiple myeloma, including allogeneic products, dual-targeted CAR-T therapies, and novel cell engineering approaches. Dr Dhakal highlights the need to improve access, durability of response, and safety for patients with relapsed/refractory disease, and explains how off-the-shelf and rapidly manufactured CAR-T products may help overcome current logistical and treatment limitations. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
